SCHEMBL22911005

SCHEMBL22911005

CCCCCCCCCCCCC/C=C/C[C@H](CO)NC(=O)CCCCCCCCCCCCCCCCC

nearest known ligand 0.72

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PLA2G4A P47712 1/20 0.65
DEGS1 O15121 1/20 0.61
CNR1 P21554 1/20 0.61
CETP P11597 3/20 0.60
THRB P10828 2/20 0.59
MEN1 O00255 1/20 0.59
KMT2A Q03164 1/20 0.59
KCNK3 O14649 1/20 0.58
ALDH1A1 P00352 1/20 0.58
CNR2 P34972 1/20 0.58
BLM P54132 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
FAAH O00519 3/20 0.56
LPAR3 Q9UBY5 1/20 0.55
HRH3 Q9Y5N1 1/20 0.55
ASAH2 Q9NR71 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15295511 1.00 PLA2G4A (0.65) PLA2G4ADEGS1CNR1CETPTHRB
SCHEMBL22911038 1.00 PLA2G4A (0.65) PLA2G4ADEGS1CNR1CETPTHRB
SCHEMBL22910834 1.00 PLA2G4A (0.65) PLA2G4ADEGS1CNR1CETPTHRB
SCHEMBL22910816 1.00 PLA2G4A (0.65) PLA2G4ADEGS1CNR1CETPTHRB
SCHEMBL22910819 1.00 PLA2G4A (0.65) PLA2G4ADEGS1CNR1CETPTHRB
SCHEMBL23016760 1.00 PLA2G4A (0.65) PLA2G4ADEGS1CNR1CETPTHRB
SCHEMBL22911231 1.00 PLA2G4A (0.65) PLA2G4ADEGS1CNR1CETPTHRB
SCHEMBL22910798 1.00 PLA2G4A (0.65) PLA2G4ADEGS1CNR1CETPTHRB
SCHEMBL22910840 1.00 PLA2G4A (0.65) PLA2G4ADEGS1CNR1CETPTHRB
SCHEMBL21428472 0.97 PLA2G4A (0.62) PLA2G4ADEGS1CNR1CETPTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210015767-A1 ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) 2021-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210015767-A1 ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID SPHK2, SPHK1, S1PR2 PLA2G4A 65/4885DEGS1 41/4885CNR1 378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.